Catalent to Continue Operating as CDMO After Novo Holdings Buyout, CEO Says

MT Newswires Live00:35

Catalent (CTLT) Chief Executive Alessandro Maselli said Monday that the company will continue to operate as a contract development and manufacturing organization, or CDMO, after its acquisition by Novo Nordisk's (NVO) controlling shareholder Novo Holdings.

In an open letter to customers Monday, Maselli said he would continue as CEO and president of Catalent as he sought to reassure customers, saying Catalent will continue to meet its existing commitments while protecting customers' proprietary production and ingredient information after the deal closes.

Novo Holdings announced plans to buy Catalent in February, with the deal valuing the target company at $63.50 per share.

The buyout is expected to close before the end of 2024, subject to regulatory and shareholder approvals and other customary conditions, the companies have said.

Price: 60.26, Change: -0.03, Percent Change: -0.05

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2477895608?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-22 00:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2477895608","market":"nz","top_or_hot":-1,"title":"Catalent to Continue Operating as CDMO After Novo Holdings Buyout, CEO Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CTLT\">Catalent</a> (CTLT) Chief Executive Alessandro Maselli said Monday that the company will continue to operate as a contract development and manufacturing organization, or CDMO, after its acquisition by Novo Nordisk's (NVO) controlling shareholder Novo Holdings.</p><p>In an open letter to customers Monday, Maselli said he would continue as CEO and president of Catalent as he sought to reassure customers, saying Catalent will continue to meet its existing commitments while protecting customers' proprietary production and ingredient information after the deal closes.</p><p>Novo Holdings announced plans to buy Catalent in February, with the deal valuing the target company at $63.50 per share.</p><p>The buyout is expected to close before the end of 2024, subject to regulatory and shareholder approvals and other customary conditions, the companies have said.</p><p>Price: 60.26, Change: -0.03, Percent Change: -0.05</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Catalent to Continue Operating as CDMO After Novo Holdings Buyout, CEO Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCatalent to Continue Operating as CDMO After Novo Holdings Buyout, CEO Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-22 00:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Catalent (CTLT) Chief Executive Alessandro Maselli said Monday that the company will continue to operate as a contract development and manufacturing organization, or CDMO, after its acquisition by ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTLT","symbol_name":"Catalent","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2477895608","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477895608","pubTimestamp":1729528531,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Catalent  Chief Executive Alessandro Maselli said Monday that the company will continue to operate as a contract development and manufacturing organization, or CDMO, after its acquisition by Novo Nordisk's  controlling shareholder Novo Holdings.In an open letter to customers Monday, Maselli said he would continue as CEO and president of Catalent as he sought to reassure customers, saying Catalent will continue to meet its existing commitments while protecting customers' proprietary production and ingredient information after the deal closes.Novo Holdings announced plans to buy Catalent in February, with the deal valuing the target company at $63.50 per share.The buyout is expected to close before the end of 2024, subject to regulatory and shareholder approvals and other customary conditions, the companies have said.Price: 60.26, Change: -0.03, Percent Change: -0.05","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"CTLT":"Catalent","CDMO":"Avid Bioservices, Inc.","NVO":"诺和诺德"},"translate_title":"康泰伦特首席执行官表示，Novo Holdings收购后将继续作为CDMO运营","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDMO":1,"CTLT":1,"NVO":0.9},"content_text":"Catalent (CTLT) Chief Executive Alessandro Maselli said Monday that the company will continue to operate as a contract development and manufacturing organization, or CDMO, after its acquisition by Novo Nordisk's (NVO) controlling shareholder Novo Holdings.In an open letter to customers Monday, Maselli said he would continue as CEO and president of Catalent as he sought to reassure customers, saying Catalent will continue to meet its existing commitments while protecting customers' proprietary production and ingredient information after the deal closes.Novo Holdings announced plans to buy Catalent in February, with the deal valuing the target company at $63.50 per share.The buyout is expected to close before the end of 2024, subject to regulatory and shareholder approvals and other customary conditions, the companies have said.Price: 60.26, Change: -0.03, Percent Change: -0.05","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2477895608"}